文献速递神经肌肉病

Rasch构建的肌萎缩侧索硬化整体残疾量表的开发与验证

Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS).
PubMed 文献 · JAMA Neurol · 2020-01-01

本研究基于Rasch方法开发并验证了28条目的自评肌萎缩侧索硬化(ALS)整体残疾量表ROADS。243例ALS患者完成初稿问卷,230例纳入Rasch分析。ROADS满足Rasch模型要求,条目靶向性优于ALSFRS-R,重测信度为0.97,可作为ALS临床试验和临床实践的结果测量工具。

要点

  • ROADS为28条目自评量表,每条目评分0、1或2分。
  • ROADS满足Rasch模型要求,重测信度为0.97。
  • ROADS条目靶向性优于ALSFRS-R,后者违反Rasch模型预期。

核心结论

  • ROADS是线性加权的28条目自评量表,条目靶向性优于ALSFRS-R,重测信度高,已验证可用于ALS试验和临床。

研究设计与样本

  • 基于文献回顾、专家小组临床判断和患者意见创建含119个问题的初步ALS残疾问卷。
  • 2017年1月至2019年6月从Emory大学和亚特兰大VA医学中心ALS门诊连续招募患者完成初稿问卷和ALSFRS-R。
  • 509例ALS患者就诊,264例提供知情同意,243例完成初稿问卷,230例纳入Rasch分析。

主要发现

  • 研究参与者平均年龄61.9(11.1)岁,146例(60.1%)为男性。
  • 起病部位为延髓23.0%(n=56)、上肢36.2%(n=88)、下肢39.5%(n=96)。
  • 构建的ROADS含28个条目,每条目评分0、1或2分。
  • ROADS满足Rasch模型要求,条目靶向性优于ALSFRS-R,重测信度为0.97。
  • ALSFRS-R违反Rasch模型预期,12个问题中9个呈现无序阈值,48个答案选项中13个从未是最可能答案。

关键数值与推荐

  • ROADS条目拟合统计量infit值范围为0.68至1.37,outfit值范围为0.66至1.43。
  • 实测方差解释与模型方差差异为0.1%。

临床怎么用

  • ROADS可作为ALS临床试验和临床实践中易于获取的结果测量工具,反应性优于ALSFRS-R。

局限性

  • 研究仅纳入两个中心的患者,样本量有限,可能影响普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: A new outcome measure for overall disability level with improved responsiveness is needed for amyotrophic lateral sclerosis (ALS) clinical trials. OBJECTIVE: To describe the creation and development of a new self-reported ALS disability scale with improved item targeting and psychometric properties that used a mathematically rigorous Rasch methodology. DESIGN, SETTING, AND PARTICIPANTS: A preliminary ALS disability questionnaire with 119 questions was created based on literature review, clinical judgement of an expert panel, and patient input. Patients with ALS were recruited from January 2017 to June 2019 from the Emory University and Atlanta VA Medical Center ALS clinics, both in Atlanta, Georgia, during regularly scheduled clinic appointments to complete the draft questionnaire and standard ALS outcome measures. All consecutive patients seen at the Emory University and Atlanta VA Medical Center ALS clinics during the recruitment period with a diagnosis of ALS who were able to provide informed consent were invited to participate in the study. Rasch analyses were performed, and items were systematically removed based on missing data, model fit, disordered thresholds, item bias, and clinical judgment. A total of 509 patients with ALS were seen at the 2 sites during the recruitment period, and 264 patients provided informed consent. INTERVENTIONS: Participants completed the draft Rasch questionnaire and the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R). MAIN OUTCOMES AND MEASURES: Rasch analyses and standard scale metrics were performed to create the new scale, and Rasch analyses were performed on the ALSFRS-R for comparison. RESULTS: Overall, 243 participants with ALS completed the draft questionnaire, and 230 participants were included for Rasch analyses. The mean (SD) age for study participants was 61.9 (11.1) years, 146 (60.1%) were men, and site of onset was 23.0% bulbar (n = 56), 36.2% upper extremity (n = 88), and 39.5% lower extremity (n = 96). A 28-question Rasch-Built Overall ALS Disability Scale (ROADS) was constructed with each item scored 0, 1, or 2. The ROADS fulfilled Rasch model requirements, demonstrated improved item targeting compared with the ALSFRS-R, and had test-retest reliability of 0.97. Individual question fit statistics demonstrated infit values from 0.68 to 1.37 and outfit values from 0.66 to 1.43. The difference between the empirical variance explained by the measures and the modeled variance was 0.1%. The ALSFRS-R violated Rasch model expectations and demonstrated disordered thresholds for 9 of 12 questions; 13 of 48 answer choices on the ALSFRS-R were never the most probable answer choice for any overall disability level. CONCLUSIONS AND RELEVANCE: In this study, the 28-question, self-reported ROADS, which is linearly weighted, had improved item targeting compared with the ALSFRS-R, had high test-retest reliability, and was validated. ROADS may serve as a valuable and easily accessible outcome measure for use in ALS trials and in the clinic with improved responsiveness compared with the ALSFRS-R.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Fournier CN, Bedlack R, Quinn C, et al. Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS). JAMA Neurol. 2020. PMID: 31886839. doi:10.1001/jamaneurol.2019.4490

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。